

## Pan-Canadian Pharmaceutical Alliance: Active Negotiations

As of October 31, 2019

There are 42 negotiations **currently underway** for the following drug products:

Drug Product Brand Name (Generic Name)	Indication/Use
<b>Adlyxine (lixisenatide)</b>	Used to treat Type 2 diabetes mellitus
<b>Bosulif (bosutinib)</b>	Used to treat chronic myeloid leukemia.
<b>Brineura (cerliponase alfa)</b>	Used to treat neuronal ceroid lipofuscinosis type 2
<b>Cabometyx (cabozantinib)</b>	Used to treat renal cell carcinoma
<b>Cresemba (isavuconazole)</b>	Used to treat invasive aspergillosis and mucormycosis
<b>Dovato (dolutegravir/lamivudine)*</b>	Used to treat HIV infection
<b>Emerade (epinephrine bitartrate)</b>	Used for the emergency treatment of anaphylactic reactions
<b>Folotyn (pralatrexate)</b>	Used to treat peripheral T-cell lymphoma
<b>Herzuma (trastuzumab)</b>	Used to treat early breast cancer, metastatic breast cancer, and gastric cancer
<b>Humira (citrate free) (adalimumab)</b>	Used for multiple indications
<b>Ibrance/Faslodex (palbociclib/fulvestrant)</b>	Used to treat advanced or metastatic breast cancer
<b>Januvia (sitagliptin)</b>	Used to treat Type 2 diabetes mellitus
<b>Kanuma (sebelipase alfa)</b>	Used to treat lysosomal acid lipase deficiency
<b>Keytruda (pembrolizumab)</b>	Used to treat classic Hodgkin lymphoma
<b>Keytruda (pembrolizumab)</b>	Used to treat melanoma adjuvant therapy
<b>Keytruda (pembrolizumab)</b>	Used to treat metastatic urothelial carcinoma
<b>Keytruda (pembrolizumab)</b>	Used to treat metastatic non-squamous non-small cell lung cancer
<b>Kuvan (sapropterin dihydrochloride)</b>	Used to treat Phenylketonuria (PKU)
<b>Lenvima (lenvatinib)</b>	Used for first-line treatment of unresectable hepatocellular carcinoma
<b>Lutathera (lutetium Lu-177)</b>	Used to treat midgut neuroendocrine tumours
<b>Mavenclad (cladribine)</b>	Used to treat relapsing-remitting multiple sclerosis
<b>Mezera (mesalazine)*</b>	Used to treat ulcerative colitis
<b>Olumiant (baricitnib)</b>	Used to treat rheumatoid arthritis
<b>Opsumit (macitentan)</b>	Used to treat pulmonary arterial hypertension
<b>Orfadin Oral Suspension (nitisinone)</b>	Used to treat hereditary tyrosinemia type 1 (HT-1)
<b>Prevymis (letermovir)</b>	Used for the prevention of cytomegalovirus infection
<b>Radicava (edaravone)</b>	Used to treat amyotrophic lateral sclerosis
<b>Revlimid (lenalidomide)</b>	Used to treat multiple myeloma
<b>Segluromet (ertugliflozin/metformin hydrochloride)</b>	Used to treat Type 2 diabetes mellitus
<b>Skyrizi (risankizumab)</b>	Used to treat plaque psoriasis
<b>Soliqua (lixisenatide/insulin glargine)</b>	Used to treat Type 2 diabetes mellitus
<b>Steglatro (ertugliflozin)</b>	Used to treat Type 2 diabetes mellitus
<b>Sublocade (buprenorphine)</b>	Used to treat opioid dependence
<b>Tagrisso (osimertinib)</b>	Used to treat first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)

<b>Truxima (rituximab)</b>	Used to treat rheumatoid arthritis, chronic lymphocytic leukemia, and non-Hodgkin's lymphoma
<b>Verzenio (abemaciclib)</b>	Used to treat advanced or metastatic breast cancer
<b>Vizimpro (dacomitinib)</b>	Used to treat locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR)-activating mutations
<b>Vyzulta (latanoprostene bunod)</b>	Used to treat open-angle glaucoma or ocular hypertension.
<b>Xalkori (crizotinib)</b>	Used to treat ROS1-positive advanced non-small cell lung cancer
<b>Xarelto (rivaroxaban)</b>	Used for the prevention of cardiovascular events in coronary and peripheral artery disease
<b>Xeljanz (tofacitinib)</b>	Used to treat ulcerative colitis
<b>Xtandi (enzalutamide)</b>	Used to treat high risk non-metastatic castrate resistant prostate cancer

\* New drug products since last update of September 30, 2019.